-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QSkPSpmkQBHGoO3WOljcyEnHB6NVeHRcSuikKEFt3RTQswqRlvOGO+w5GwxhfslT Spi2w9P4meRfq73gbqjCUQ== 0000875320-08-000064.txt : 20080807 0000875320-08-000064.hdr.sgml : 20080807 20080807124727 ACCESSION NUMBER: 0000875320-08-000064 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080730 FILED AS OF DATE: 20080807 DATE AS OF CHANGE: 20080807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6165776000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BOGER JOSHUA S CENTRAL INDEX KEY: 0001197023 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 08997523 MAIL ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4/A 1 edgar.xml PRIMARY DOCUMENT X0303 4/A 2008-07-30 2008-07-31 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001197023 BOGER JOSHUA S C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE MA 02139 1 1 0 0 President & CEO Common Stock 2008-07-30 4 M 0 12400 10.19 A 1107444 D Common Stock 2008-07-30 4 S 0 2584 32.38 D 1104860 D Common Stock 2008-07-30 4 S 0 9816 32.91 D 1095044 D Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $32.38 (range $31.58 to $32.57). Open market sales reported on this line occurred at a weighted average price of $32.91 (range $32.59 to $33.25). Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Amount of securities beneficially owned following reported transaction was incorrect in original filing. Valerie L. Andrews 2008-08-07 -----END PRIVACY-ENHANCED MESSAGE-----